And so when you have a patient in your office, one, as a primary care frontline doctor, its very important to understand, if you dont set up the patient for success, they will not be successful on bariatric surgery
A theoretically sophisticated product provides little value if it is unpleasant, difficult to store or used inconsistently
NICE guidance (NG28) supports the use of GLP-1 receptor agonists like semaglutide in combination with other glucose-lowering therapies, including sulfonylureas, when clinically appropriate and within specific criteria
doi: 10.1016/j.nicl.2014.09.002 33 HuberJ
Heres why this matters so much for those with hypermobility and EDS
Extending the interval to fortnightly dosing represents off-label use without supporting evidence, potentially compromising therapeutic outcomes